WC
AVBP icon

Wexford Capital’s ArriVent BioPharma AVBP Stock Holding History

Wexford Capital’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,567
Closed -$28.9K – 550
2025
Q3 		$28.9K Sell
1,567
-3,952
-72% -$77.6K ﹤0.01% 369
2025
Q2 		$120K Buy
+5,519
New +$115K 0.03% 202

Other funds holding AVBP

IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wexford Capital's AVBP Position: Q4 2025 in Review

Wexford Capital sold out of ArriVent BioPharma (AVBP) in Q4 2025, closing a stake of 1,567 shares — an estimated $28.9K sold.

Wexford Capital first reported a position in AVBP in Q2 2025 and held it in 2 quarters. The position peaked at $120K in Q2 2025. 121 funds tracked by Wall St. Rank hold AVBP as of Q4 2025.

  • Wexford Capital reported no remaining ArriVent BioPharma position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 1,567 ArriVent BioPharma shares in Q4 2025, an estimated $28.9K.
  • Wexford Capital first reported a position in ArriVent BioPharma in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's ArriVent BioPharma position peaked at $120K in Q2 2025.
  • 121 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.